Jiangsu Sihuan Bioengineering 

Jiangsu Sihuan Bioengineering Co., Ltd. is a Chinese pharmaceutical company. Its product portfolio includes anti-cancer biotherapeutics such as Drewson, prescribed for renal cancer, malignant melanoma, and cancerous effusions in the chest and abdomen. Another significant oncology drug, Xinde Lusheng, targets a much wider spectrum of malignancies, including kidney, melanoma, lung, gastric, malignant lymphoma, breast, ovarian, bowel, bladder, head and neck tumors, and leukemia, in addition to cancerous pleural effusions. Beyond oncology, the company also produces Xin grain health, a recombinant human granulocyte colony stimulating factor (G-CSF) injection. Additionally, Tourbo, a recombinant human erythropoietin (EPO) injection, addresses anemia stemming from kidney dysfunction in both dialysis-dependent and non-dialysis patients. Established in 1992, Jiangsu Sihuan Bioengineering is headquartered in Jiangyin, China.